Anticoagulants: Market Research Report

January 2019 | 285 pages | ID: A3E77FDF275EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

• Abbott India Limited
• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Mitsubishi Tanabe Pharma Corporation

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Oral Anticoagulants
Injectable Anticoagulants

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

Venous ThromboEmbolism (VTE) – A Prelude
Anticoagulants Market Driven by Novel Oral Anti-coagulants
Sizing the Market
Safety Issues Associated with Erstwhile Market Leaders – Warfarin & Heparins
Anticoagulants – Evolution from Injectables to Oral Drugs
Conventional Oral Drug – Warfarin – Face the Heat
The Newer Breed of NOACs
Comparative Analysis of Warfarin and Novel Oral Anticoagulants

Table 1. Global Market for Leading Oral Drugs (2016): Percentage Market Share Breakdown of Value Sales for Eliquis, Xarelto, Pradaxa, and Others (includes corresponding Graph/Chart)

Bevyxxa (Betrixaban) – The Latest Approved NOAC
Aging Population: A Crucial Driver for Anticoagulants Market

Table 2. Global Population Statistics for the 60+ Age Group by Region (2017) (includes corresponding Graph/Chart)

Table 3. Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)

Table 4. Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Table 5. Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

Table 6. Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)

Global Menace of Cardiovascular Disease – A Major Growth Factor

Table 7. Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)

Table 8. Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

Increasing Prevalence of AF Impacts Growth Prospects
Rising Stroke Statistics – An Opportunity Indicator for Anticoagulants
Increasing Incidence of Knee/Hip Replacement Surgeries Drive Market Growth

Table 9. Hip Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)

Table 10. Knee Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)

Increasing Healthcare Spending in Emerging Markets

Table 11. Healthcare Spending as a Percentage of GDP by Region: 2016 (includes corresponding Graph/Chart)

Table 12. Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2016) (includes corresponding Graph/Chart)

Adverse Effects: A Key Market Deterrent
Common Adverse Effects of NOAC Therapies
Increased Bleeding – A Major Concern with Newer Agents
Novel Oral Drugs: Absence of Antidote & Other Concerns
US FDA Delays Andexxa (the Xarelto and Eliquis Antidote) Approval
Reversal Agents for DOACs
Threat of Generics Looms Large on the Anti-Coagulants Market
Patent Expiries of Oral Anticoagulants
Pipeline Analysis
Tecarfarin (Espero BioPharma)
List of Ongoing NOAC Studies

2. MARKET TRENDS & ISSUES

NOACs to Emerge as Mainstream Option for VTE Patients
NICE Guidelines Promote NOAC Usage in Atrial Fibrillation
NOACs as Alternative/Supplement to Antiplatelet Therapy
Increase in Heparin Trade Boosts the Market
Modern Developments Improving Anticoagulation Management
Researchers Find Significant Correlation between NAOC and Newer Health Risks
NOAC Underdosing Trend Restrains Universal Acceptance
Underutilization of Oral Anticoagulants in Atrial Fibrillation
Generics Prevail in the Traditional Market
Patent Expiries of Traditional Anticoagulants in the US
Inadequate Trials Mar Pediatric Anticoagulants Market
New Advancements Improve Anticoagulation Management
Growing Demand for Self-Testing
LMWHs Ease Outpatient Management

3. SEGMENT ANALYSIS

Oral Anticoagulant Agents
Traditional Oral Anticoagulants
Warfarin
Coumadin – The Branded Warfarin
Advantages and Alternatives
Side Effects
Limitations
Novel Oral AntiCoagulants (NOAC)
Approved Indications of Various NOACs by Geographic Region
Approved Anticoagulant Agents in a Nutshell
Pradaxa (Dabigatran Etexilate)
Pradaxa and Warfarin - A Comparative Study
Xarelto (Rivaroxaban)
Xarelto Patent Expiry in Various Regions
Apixaban (Eliquis)
Savaysa (Edoxaban)
Bevyxxa (betrixaban)
Injectable Anticoagulants
Injectable Anticoagulants – An Insight
Heparin – The Backbone of Injectable Anticoagulants
Unfractionated Heparin
Advantages and Alternatives
Limitations
Low Molecular Weight Heparins (LMWH)
Indications
Advantages
A Focus on Select Heparin-based Injectables
Lovenox/Clexane (enoxaparin)
Approved Indications for Lovenox
Advantages and Alternatives
Fragmin (dalteparin sodium)
Approved Indications for Fragmin Use
Fraxiparine (nadroparin)
Innohep (tinzaparin)
Normiflo (ardeparin)
Clivarine (reviparin)
Non-Heparin Anticoagulant Injectables – An Overview
Arixtra (fondaparinux)
Angiomax (bivalirudin)
Advantages
Argatroban/Novastan
Side Effects

4. THERAPEUTIC INDICATIONS

Venous/DVT Thrombosis Indications
Venous Thromboembolism
Venous Thromboembolism—Causes and Symptoms
Deep Vein Thrombosis
Pulmonary Embolism
Orthopedic (Hip or Knee Replacement) Surgery
General Surgery
Cancer
Arterial Thrombosis Indications
Arterial Thrombosis
Acute Coronary Syndromes
Atrial Fibrillation
Unstable Angina
List of Approved Anticoagulants for Unstable Angina
Myocardial Infarction
Non ST-Segment Elevation MI
Percutaneous Transluminal Coronary Angioplasty (PTCA)
Heparin Induced Thrombocytopenia (HIT) Indications
Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
Other Indications
Hemodialysis

5. PRODUCT INTRODUCTIONS/APPROVALS

Mylan Pharmaceuticals Inc. Agrees to hold off Pradaxa’s generic version
Portola Pharmaceuticals Declares Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
Daiichi Sankyo Introduces Anticoagulant Lixiana OD Tablets
FDA again Delays Approval of AndexXa
US FDA Approves Bayer’s Xarelto
Portola Pharmaceuticals Receives U. S FDA Approval for Bevyxxa
Armetheon Receives European Medicines Agency’s Support for Studying Tecarfarin prior to MAA Filing
Armetheon Agrees with FDA for Conducting a Study for Tecarfarin Prior to NDA Filing
Rivaroxaban (Xarelto) Receives Patent Term Extension in US
Armetheon Declares Positive Results of Tecarfarin versus Warfarin
FDA Approves Pradaxa Antidote Praxbind
CFDA Approves Bayer’s Xarelto
Raplixa Anticoagulant by MDCO Receives FDA Approval
Teva Launches Argatroban Injection in the US Market
BMS and Pfizer Announce Phase III Results of Apixaban
Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA
FDA Grants Fast Track Designation to Perosphere’s PER977
FDA Approves Savaysa/Edoxaban

6. RECENT INDUSTRY ACTIVITY

Daiichi Sankyo Introduces Anticoagulant Lixiana OD Tablets in Japan
Bristol-Myers Squibb and Pfizer Presents New Analyses for Eliquis (apixaban) Clinical and Real-World Data
Espero Pharmaceuticals and Armetheon Plans to Merge
Portola Pharmaceuticals Signs a Loan Agreement with Pfizer and Bristol-Myers Squibb
Momenta Pharmaceuticals Presents Data on Necuparanib at the ASCO Annual Meeting
Reig Jofre Acquires Chiesi España SA a sodium heparin
Chiesi Acquires Three Hospital Products - Kengreal, Cleviprex and Argatroban for Injection
Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto
Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals

7. FOCUS ON SELECT GLOBAL PLAYERS

Abbott India Limited (India)
Aspen Holdings (South Africa)
Bayer AG (Germany)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Company (USA)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer, Inc. (USA)
Sanofi S. A. (France)
Teva Pharmaceutical Industries Ltd. (Israel)

8. GLOBAL MARKET PERSPECTIVE

Table 13. World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 14. World Historic Review for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 15. World 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 16. World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 17. World Historic Review for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 18. World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 19. World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 20. World Historic Review for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 21. World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 22. World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 23. World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 24. World 14-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 25. World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 26. World Historic Review for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 27. World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 28. World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 29. World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 30. World 14-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Key Statistics
US: The Largest Market for Anti-Coagulants
A List of FDA Approved Anticoagulants
Eliquis and Xarelto lead the US NOAC Market

Table 31. The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Prescriptions for Warfarin, Xarelto, Eliquis, Pradaxa, and Savaysa (includes corresponding Graph/Chart)

Table 32. The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Sales for Xarelto, Eliquis, Pradaxa, and Others (includes corresponding Graph/Chart)

AndexXa – Another Reversal Agent for NOAC
Growth Drivers/Trends
Atrial Fibrillation – A Key Risk Factor, Driving the Demand for Anti-Coagulants
Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market

Table 33. North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Surge in CVD Incidence – Major Growth Factor

Table 34. CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)

Table 35. Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)

Manufacturers’ Patient Assistance Programs Support Increased Sales
US Injectable Anti-Coagulants Market
Decline in Heparin Demand
Extending the Use of Heparin to New Indications
Product Introductions/Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 36. The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 37. The US Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 38. The US 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

Market Analysis

Table 39. Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 40. Canadian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 41. Canadian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Graying Population Spurs Growth of Anticoagulants

Table 42. Japanese Aging Population by Age Group: Year Ending June 1, 2017 (includes corresponding Graph/Chart)

Product Launches
Select Key Players
B. Market Analytics

Table 43. Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 44. Japanese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 45. Japanese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Europe: A Major Anti-Coagulant Market
Increasing Aging Population Boosts Demand

Table 46. Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart)

New Drugs Drive Use of Oral Anticoagulants in Atrial Fibrillation Patients
B. Market Analytics

Table 47. European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 48. European Historic Review for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 49. European 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 50. European Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 51. European Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 52. European 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Sanofi S. A. – A Key Player
B. Market Analytics

Table 53. French Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 54. French Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 55. French 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Strategic Corporate Developments
Focus on Select Key Players
B. Market Analytics

Table 56. German Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 57. German Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 58. German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 59. Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 60. Italian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 61. Italian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Stroke Statistics – Opportunity Indicator for Anticoagulants
NICE Guidelines Promote NOAC Usage
B. Market Analytics

Table 62. The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 63. The UK Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 64. The UK 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4E. SPAIN

A. Market Analysis
Strategic Corporate Development
B. Market Analytics

Table 65. Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 66. Spanish Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 67. Spanish 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 68. Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 69. Russian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 70. Russian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

Market Analysis

Table 71. Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 72. Rest of Europe Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 73. Rest of Europe 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Highly Populated Asian Countries Offer Significant Growth Opportunities

Table 74. Over 65 Years Individuals as % of the Total Population in Select Asian Countries: 2016 (includes corresponding Graph/Chart)

B. Market Analytics

Table 75. Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 76. Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 77. Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 78. Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 79. Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 80. Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5A. CHINA

A. Market Analysis
Favorable Reimbursement for NOACs
LMWH – The leading Heparin Segment
Product Launch
B. Market Analytics

Table 81. Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 82. Chinese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 83. Chinese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
Abbott India Limited – A Key Player
B. Market Analytics

Table 84. Indian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 85. Indian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 86. Indian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

Market Analysis

Table 87. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 88. Rest of Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 89. Rest of Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. LATIN AMERICA

Market Analysis

Table 90. Latin American Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 91. Latin American Historic Review for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 92. Latin American 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 93. Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 94. Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 95. Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6A. BRAZIL

Market Analysis

Table 96. Brazilian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 97. Brazilian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 98. Brazilian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6B. REST OF LATIN AMERICA

Market Analysis

Table 99. Rest of Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 100. Rest of Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 101. Rest of Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. Market Analysis
Select Key Players
B. Market Analytics

Table 102. Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 103. Rest of World Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 104. Rest of World 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 48 (including Divisions/Subsidiaries - 58)
The United States (23)
Japan (3)
Europe (30)
  France (1)
  Germany (4)
  The United Kingdom (4)
  Spain (1)
  Rest of Europe (5)
Asia-Pacific (Excluding Japan) (15)
Africa (2)